GUÍA MANEJO ANTIRRETROVIRAL PERSONAS VIH

in Mexican HIV Clinics. Open Forum Infectious Diseases. 2014.
1(2): 1-7.
70. Gallant JE. Making Sense of Blips. J Infect Dis.2007;196:1729-
31.
71. Grennan JT, Loutfy MR, Su DS, et al. Magnitude of virologic blips
is associated with a higher risk for virologic rebound in HIVinfected
individuals: a recurrent events analysis. J Infect Dis.
2012;205:1230-8.
72. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance
in HIV type 1-infected patients after receipt of first-line highly
active antiretroviral therapy: a systematic review of clinical trials.
Clin Infect Dis. 2008;47:712-22.
73. Hamers RL, Sigaloff KCE, Wensing AM, et al. Patterns of HIV-1
drug resistance after first-line antiretroviral therapy (ART) failure
in 6 Sub-Saharan African Countries: implications for second-line
ART strategies. Clin Infect Dis. 2012;54(11):1660-9.
74. Humphreys EH, Chang LW, Harris J. Antiretroviral regimens for
patients with HIV who fail first-line antiretroviral therapy
(Review). The Cochrane collaboration. Wiley. 2011.
75. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and
virologic evolution during periods of intermittent and persistent
low-level viremia. AIDS. 2004;18(7):981-989.
76. Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H.
Virologic failure following persistent low-level viremia in a cohort
of HIV-positive patients: results from 12 years of observation.
Clin Infect Dis. 2013;57(10):1489-1496. Disponible en
http://www.ncbi.nlm.nih.gov/pubmed/23946221.
77. Lee PK, Kieffer TL, Siliciano RF, et al. HIV-1 viral load blips are
of limited clinical significance. Journal of Antimicrobial
Chemotherapy 2006;57:803-805.
78. Manavi K. The significance of low-level plasma HIV viral load on
COBAS TaqMan® HIV-1 assays for patients with undetectable
plasma viral load on COBAS Amplicor® monitor vesion 1.5. HIV
Clin Trials 2008;9(4):283-286.
79. Mocroft A, Phillips AN, Miller V, et al. The use of and response to
second-line protease inhibitor regimens: results from the
EuroSIDA study. AIDS. 2001;15:201-209.
80. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia
(Blips) and drug resistance in patients receiving HAART. JAMA.
2005;293(7):817-829.
81. Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance
in HIV-1-infected patients with persistently detectable low-level
viremia while receiving highly active antiretroviral therapy. Clin
Infect Dis. 2004;39:1030-7.
82. Scherrer AU, Böni J, Yerly S, et al. Long-lasting protection of
activity of nucleoside reverse transcriptase inhibitors and protease
inhibitors (PIs) by boosted PI containing regimens. Plos One
2012(7);11:e50307.
83. Sigaloff KCE, Hamers RL, Wallis CL, et al. Second-Line
Antiretroviral Treatment Successfully Resuppresses Drug-
Resistant HIV-1 After First-Line Failure: Prospective Cohort in
Sub-Saharan Africa. J. Infect. Dis.2012;205:1739-44.
84. Swenson LC, Min JE, Woods CK, et al. HIV drug resistance
detected during low-level viraemia is associated with subsequent
virologic failure. AIDS. 2014;28:1125-1134.
85. Taiwo B, Bosch RJ. More reasons to reexamine the definition of
viral blip during antiretroviral therapy.J. Infect.
Dis.2012;205:1189-91.
86. Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in
HIV-1-infected patients experiencing persistent low-level viremia
during first-line therapy. J. Infect. Dis.2011;204:515-20.
87. Taiwo B, Gallien S, Aga S, al e. HIV drug resistance evolution
during persistent near-target viral suppression. Antiviral
Therapy.2010;15:A38.
88. Waters L, Bansi L, Asboe D, et al. Second-line protease inhibitorbased
antiretroviral therapy after non-nucleoside reverse
transcriptase inhibitor failure: the effect of a nucleoside backbone.
Antiviral Therapy.2013;18:213-219.
89. Gale HB, Gitterman SR, Hoffman HJ, et al. Is frequent CD4+ T-
lymphocyte count monitoring necessary for persons with counts
>=300 cells/muL and HIV-1 suppression? Clin Infect Dis.
2013;56(9):1340-1343.
90. Girard PM, Nelson M, Mohammed P, Hill A, van Delft Y,
Moecklinghoff C. Can we stop CD4+ testing in patients with HIV-
1 RNA suppression on antiretroviral treatment? AIDS.
2013;27(17):2759-2763.
91. Human immunodeficiency virus type 1 RNA level and CD4 count
as prognostic markers and surrogate end points: a meta-analysis.
HIV Surrogate Marker Collaborative Group. AIDS Res Hum
Retroviruses. 2000;16(12):1123-1133.
92. Hyle EP, Sax PE, Walensky RP. Potential savings by reduced CD4
monitoring in stable patients with HIV receiving antiretroviral
therapy. JAMA Intern Med. 2013;173(18):1746-1748.
93. Moore RD, Keruly JC. CD4+ cell count 6 years after
commencement of highly active antiretroviral therapy in persons
with sustained virologic suppression. Clin Infect Dis.
2007;44(3):441-446.
94. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial:
darunavir/ritonavir with or without nucleoside analogues, for
patients with HIV RNA below 50 copies/ml. AIDS.
2010;24(2):223-230.
95. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher
CA. HIV monotherapy with ritonavir-boosted protease inhibitors:
a systematic review. AIDS. 2009;23(3):279-291.
96. Bonjoch A, Pou C, Perez-Alvarez N, et al. Switching the third drug
of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot,
prospective, randomized clinical trial. J Antimicrob Chemother.
2013;68(6):1382-1387.
97. Burgos J, Crespo M, Falco V, et al. Simplification to dual
antiretroviral therapy including a ritonavir-boosted protease
inhibitor in treatment-experienced HIV-1-infected patients. J
Antimicrob Chemother. 2012;67(10):2479-2486.
98. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based
regimen versus continuation of a lopinavir-ritonavir basedregimen
in stable HIV-infected patients with suppressed viraemia
(SWITCHMRK 1 and 2): two multicentre, double-blind,
randomised controlled trials. Lancet. 2010;375(9712):396-407.
99. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of
atazanavir-based highly active antiretroviral therapy in patients
with virologic suppression switched from a stable, boosted or
unboosted protease inhibitor treatment regimen: the SWAN Study
(AI424-097) 48-week results. Clin Infect Dis.
2007;44(11):1484-1492.
100. Martinez E, Larrousse M, Llibre JM, et al. Substitution of
raltegravir for ritonavir-boosted protease inhibitors in
HIVinfected patients: the SPIRAL study. AIDS.
2010;24(11):1697-1707.
101. Martinez E. The NEFA study: results at three years. AIDS Rev.
2007;9(1):62.
102. Ofotokun I, Sheth AN, Sanford SE, et al. A switch in therapy to a
reverse transcriptase inhibitor sparing combination of
lopinavir/ritonavir and raltegravir in virologically suppressed
HIV-infected patients: a pilot randomized trial to assess efficacy
and safety profile: the KITE study. AIDS Res Hum Retroviruses.
2012;28(10):1196-1206
103. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and
simplicity for HIV-infected patients on antiretroviral therapy:
self-report of the relative importance of multiple attributes of
highly active antiretroviral therapy (HAART) regimens in
predicting adherence. J Acquir Immune Defic Syndr.
2004;36(3):808-816.
104. Vispo E, Barreiro P, Maida I, et al. Simplification From Protease
Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial.
HIV Clin Trials. 2010;11(4):197-204.
105. Vitiello P, Brudney D, MacCartney M, et al. Responses to
switching to maraviroc-based antiretroviral therapy in treated
patients with suppressed plasma HIV-1-RNA load. Intervirology.
2012;55(2):172-178.
106. Wohl D. Simplification to abacavir/lamivudine (ABC/3TC) +
atazanavir (ATV) from tenofovir/emtricitabine (TDF/FTC) +
ATV/Ritonavir (RTV, /r) maintains viral suppression and
improves bone biomarkers. Abstract H-556c. Paper presented at:
Interscience Conference on Antimicrobial Agents and
Chemotherapy; 2012.
107. Simoni J, Amico K.F., Smith L., Nelson K. Antiretroviral
adherence interventions: translating research findings to the real
world clinic. Curr HIV/AIDS Rep 2010;7(1):44-51.
108. Feebet E.R., Mallon P.W.G. HIV and HAART-associated
dyslipidemia. Open cardiovasc Med J. 2011;5:49-63.
109. Enanoria W.T.A., Ng C, Saha S.R., Colford J.M. Fr, Treatment
outcomes after highly active antiretroviral therapy: a metaanalysis
of randomized controlled trials.Lancet Infect Dic
2004;4(7):414-25.
110. Bhaskaran K, Hamounda O, SannesM. Et al. changes in the risk of
death after HIV seroconversion compared with mortality in the
general population. JAMA 2008;300(1):51-9
111. Bansberg D.R., Hecht F.M., Charlebois E.D, et al.Adherence to
protease inhibitors, HIV viral load, and development of drug
resistance in an indigent population.AIDS 2000;14(4):357-66
112. Ross L, Lim LM, Wine B, et al. Prevalence of antiretroviral drug
resistance and resistance-associated mutations in antiretroviral
174